The obesity and metabolic treatment market is projected to be worth billions globally, and companies are now competing not only on clinical efficacy but also on: Market access and pricing strategies Physician education and awareness Patient adoption and long-term adherence Strategic partnerships in high-growth markets like China For example, GLP-1 products such as Wegovy have already demonstrated how strong positioning and demand can rapidly expand a therapeutic category
Results We included 3040 patients initiating treatment with GLP-1RA and 11,627 with SGLT-2i
These products are not intended to diagnose, treat, cure, or prevent any disease and are not approved for clinical, diagnostic, or therapeutic applications
The evidence-based nutrition approach we employ at Rixa Health recognizes that successful weight management requires addressing root causes, not just symptoms
Semaglutide for people without diabetes While semaglutide injection Wegovy is FDA approved for weight loss in people with and without diabetes, Ozempic and Rybelsus are not specifically cleared for weight loss use
)
